NCT02407509 2026-01-29
RAF/MEK
Royal Marsden NHS Foundation Trust
Phase 1 Completed
Clinical Trials
24 trialsNCT00655655 2024-08-21
Everolimus and Vatalanib in Treating Patients With Advanced Solid Tumors
Mayo Clinic
Phase 1 Completed
NCT04591431 2023-10-03
ROME
Fondazione per la Medicina Personalizzata
Phase 2 Unknown
NCT02890069 2023-01-11
A Study of PDR001 in Combination With LCL161, Everolimus or Panobinostat
Novartis
Phase 1 Completed
NCT02071862 2022-07-20
Study of the Glutaminase Inhibitor CB-839 in Solid Tumors
Calithera Biosciences, Inc
Phase 1 Completed
NCT00434174 2020-12-21
Safety of Everolimus and Pemetrexed in Lung Cancer Patients
Novartis
Phase 1 Completed
NCT00456833 2020-12-21
Combination of RAD001 and Erlotinib in Patients With Advanced Non Small Cell Lung Cancer Previously Treated Only With Chemotherapy
Novartis
Phase 1 Completed
NCT00466466 2020-12-21
Safety of RAD001 in Combination With Cisplatin and Etoposide in Lung Cancer Patients
Novartis
Phase 1 Completed
NCT01061788 2019-08-28
RAP
Duke University
Phase 1 Completed
NCT01115803 2019-02-05
A Study of LY2584702 With Erlotinib or Everolimus in Participants With Solid Tumors
Eli Lilly and Company
Phase 1 Terminated
NCT01470209 2018-03-19
A Phase I Study of BKM120 and Everolimus in Advanced Solid Malignancies
Emory University
Phase 1 Completed
NCT00807755 2018-01-09
Everolimus, Carboplatin, and Etoposide in Treating Patients With Small Cell Lung Cancer or Other Advanced Solid Tumors
University of California, Davis
Phase 1 Terminated
NCT00374140 2017-10-19
Phase II Trial of RAD001 (Everolimus) in Previously Treated Small Cell Lung Cancer
University of Pittsburgh
Phase 2 Completed
NCT00124280 2016-11-18
Study Investigating the Effect of Everolimus Monotherapy in Patients With Advanced Non-small Cell Lung Cancer (NSCLC)
Novartis
Phase 2 Completed
NCT00933777 2016-05-25
SORAVE
University of Cologne
Phase 1 Completed
NCT01024946 2015-05-12
Everolimus (RAD001) for the Treatment of Malignant Pleural Mesothelioma With Merlin/NF2 Loss as a Biomarker to Predict Sensitivity
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT01700400 2014-11-24
Study of Everolimus, Pemetrexed, Carboplatin, and Bevacizumab to Treat Stage IV Lung Cancer
Cancer Research and Biostatistics Clinical Trials Consortium
Phase 1 Completed
NCT01427946 2014-11-13
Phase 1b/2 Study of Retaspimycin HCl (IPI-504) in Combination With Everolimus in KRAS Mutant Non-small Cell Lung Cancer
Infinity Pharmaceuticals, Inc.
Phase 1/2 Completed
NCT01063478 2014-01-17
RAD001
University of Chicago
Phase 1 Terminated
NCT00406276 2013-08-23
Phase I/II Trial of RAD001 Plus Docetaxel in Patients With Metastatic or Recurrent Non-Small Cell Lung Cancer
Emory University
Phase 1/2 Terminated
NCT01079481 2013-05-30
Combination Anticancer Therapy of Paclitaxel and Everolimus for Relapsed or Refractory Small Cell Lung Cancer
Samsung Medical Center
Phase 1 Completed
NCT00457119 2013-02-12
Combination of RAD001 With Carboplatin, Paclitaxel and Bevacizumab in Non-small-cell Lung Cancer (NSCLC) Patients
Novartis
Phase 1 Completed
NCT01167530 2012-04-04
RAD001
Gustave Roussy, Cancer Campus, Grand Paris
Phase 1 Unknown
NCT00892801 2012-03-12
Everolimus and Whole-Brain Radiation Therapy in Treating Patients With Brain Metastasis From Non-Small Cell Lung Cancer
Vanderbilt-Ingram Cancer Center
Phase 1 Terminated